SanBio Company Limited (OTCMKTS:SNBIF) Short Interest Down 30.3% in February

SanBio Company Limited (OTCMKTS:SNBIF) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 445,400 shares, a decline of 30.3% from the January 31st total of 639,400 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 4,454.0 days.

SanBio Price Performance

SNBIF remained flat at C$6.55 during trading hours on Wednesday. The business’s 50 day simple moving average is C$5.22 and its two-hundred day simple moving average is C$4.52. SanBio has a 52 week low of C$4.65 and a 52 week high of C$6.55.

About SanBio

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.